Biotech · Private company · Peabody, MA, US
Privo Technologies
Track this companyFree. Adds Privo Technologies to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- PRV111 (Cisplatin Transmucosal System)Phase 3 · Oral Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PRV131 (Cisplatin Intratumoral Injectable)Phase 3 · Oral Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PRV211 (Intraoperative Cisplatin System)Phase 3 · Oral Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung CancersPHASE2_PHASE3 · RECRUITING · started Nov 7, 2024ClinicalTrials.gov NCT05893888 · fetched Nov 12, 2026
- Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell CarcinomaPHASE1_PHASE2 · COMPLETED · started Jun 19, 2018ClinicalTrials.gov NCT03502148 · fetched Nov 12, 2026
NIH awards4
- Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)Fiscal year 2026 · $1.2MNIH RePORTER 5R44CA281020-09 · fetched Nov 12, 2026
- Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)Fiscal year 2025 · $1.2MNIH RePORTER 5R44CA281020-08 · fetched Nov 12, 2026
- Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)Fiscal year 2024 · $2.1MNIH RePORTER 2R44CA281020-07A1 · fetched Nov 12, 2026
- Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource SettingsFiscal year 2024 · $1MNIH RePORTER 5R44CA272095-03 · fetched Nov 12, 2026